- Conditions
- Preparation for Colonoscopy
- Interventions
- Gatorade/Miralax, NuLytely, Bisacodyl, Placebo
- Drug
- Lead sponsor
- Gastroenterology Services, Ltd.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Downers Grove, Illinois
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 433–456
of 479
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Submental Fat
- Interventions
- 10XB-101 Solution for Injection
- Drug
- Lead sponsor
- 10xBio, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Rheumatoid Arthritis
- Interventions
- Cimzia, Placebo
- Drug
- Lead sponsor
- Michael Schiff, MD
- Individual
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more
- Conditions
- Prosthetic Joint Infection of Knee
- Interventions
- Intervention 1: Alternating Magnetic Field Treatment, Intervention 2 - Sham Treatment, Debridement, Antibiotics, Implant Retention
- Device · Procedure
- Lead sponsor
- Solenic Medical, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- New Albany, Ohio • Tulsa, Oklahoma
- Conditions
- Leukemia, Precursor-B Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Lymphoma
- Interventions
- Cytarabine, Daunorubicin, Vincristine, Prednisone, PEG asparaginase, Ofatumumab, Rituximab, Methotrexate, Cyclophosphamide, Mercaptopurine, Doxorubicin, Dexamethasone acetate, Thioguanine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 30 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hemophilia A
- Interventions
- PEGylated Recombinant Factor VIII, ITI
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- Up to 5 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Cupertino, California • Oakland, California + 17 more
- Conditions
- Rheumatoid Arthritis, Cardiovascular Disease
- Interventions
- Certolizumab
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 35 Years to 90 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Crohn Disease
- Interventions
- Cimzia
- Biological
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 20
- States / cities
- Lakewood, Colorado • Littleton, Colorado • New Port Richey, Florida + 16 more
- Conditions
- Dry Eye
- Interventions
- Systane Ultra Lubricant Eye Drops, Optive Lubricant Eye Drops, Blink Tears, GenTeal Moderate Lubricant Eye Drops
- Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Avascular Necrosis
- Interventions
- Alumina/Alumina, Standard
- Device
- Lead sponsor
- Encore Medical, L.P.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 342 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 3
- States / cities
- Newport Beach, California • Charleston, South Carolina • Richmond, Virginia
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
- Interventions
- L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, cytarabine, prednisone, bortezomib, pegaspargase, methotrexate, etoposide phosphate, cyclophosphamide, filgrastim, leucovorin calcium, laboratory biomarker analysis, High Dose MTX
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 1 Year to 31 Years
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 124 more
- Conditions
- Line Insertion Site, Central Line-associated Bloodstream Infection (CLABSI)
- Interventions
- Povidone-Iodine, Chlorhexidine gluconate, Pluronic Cream, control
- Drug · Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- Up to 7 Days
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Hemophilia A, Prophylaxis of Bleeding
- Interventions
- Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).
- Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 12
- States / cities
- Loma Linda, California • Los Angeles, California • Aurora, Colorado + 8 more
- Conditions
- Constipation
- Interventions
- PEG 3350, PEG-3350 with electrolytes, Glycerin
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Carmel, Indiana • Indianapolis, Indiana
- Conditions
- Healthy Volunteers
- Interventions
- LY2605541
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Rheumatoid Arthritis
- Interventions
- Certolizumab Pegol
- Biological
- Lead sponsor
- UCB Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Walnut Creek, California • Wheaton, Maryland + 3 more
- Conditions
- Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
- Interventions
- Pevonedistat, Vincristine, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Hydrocortisone
- Drug
- Lead sponsor
- Julio Barredo, MD
- Other
- Eligibility
- 16 Years to 39 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor
- Interventions
- PEG-interferon alfa-2b, bevacizumab, laboratory biomarker analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ankylosing Spondylitis
- Interventions
- Bimekizumab, Certolizumab pegol, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Ormond Beach, Florida • Lincoln, Nebraska • Oklahoma City, Oklahoma + 1 more
- Conditions
- Colonoscopy
- Interventions
- lubiprostone (Amitiza), Placebo
- Drug
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 3
- States / cities
- Detroit, Michigan • Novi, Michigan • West Bloomfield, Michigan
- Conditions
- Varicose Veins
- Interventions
- Varithena®, FDA-approved Endothermal Ablation (ETA) systems
- Drug · Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Darien, Connecticut • Washington D.C., District of Columbia • Houma, Louisiana + 6 more
- Conditions
- Crohn's Disease
- Interventions
- Fluconazole, Vancomycin, Neomycin, Ciprofloxacin, Polyethylene Glycol 3350, Promethazine, Fluconazole placebo
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- ADA-SCID, Adenosine Deaminase Deficiency, Severe Combined Immunodeficiency
- Interventions
- EZN-2279, Adagen
- Biological
- Lead sponsor
- Leadiant Biosciences, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 3 more
- Conditions
- Dry Eye Syndrome
- Interventions
- Cyclosporin A Restasis®, Blink tears, Systane
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina